Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rectal Neoplasms × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4 Breast Neoplasms 4 Neoplasms 3 Lung Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Solid Tumors 1 Rectal Neoplasms 1 Pleural Effusion 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Insulin-Like Growth Factor I, Resistance To 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Oxaliplatin 248 Fluorouracil 248 Capecitabine 204 Leucovorin 196 Irinotecan 138 Radiotherapy 128 Bevacizumab 104 Cetuximab 72 Surgical Procedures, Operative 48 Folfox protocol 46 Neoadjuvant Therapy 43 Drug Therapy 40 Radiation 36 Chemoradiotherapy 34 Chemotherapy, Adjuvant 33 Panitumumab 25 XELOX 22 Radiotherapy, Intensity-Modulated 22 Magnetic Resonance Spectroscopy 20 Proctectomy 17 Laparoscopy 17 Floxuridine 17 Surveys and Questionnaires 15 Immunohistochemistry 15 Biopsy 14 pembrolizumab 13 IFL protocol 13 Early Intervention, Educational 13 trifluridine tipiracil drug combination 12 Nivolumab 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡